IntelliHep company

IntelliHep is a spin-out company developing novel drugs for Alzheimers disease and cancer.
The company is untapping the potential of heparin-based therapeutics in biomedical applications including neurodegeneration and cancer. IntelliHep's compounds have further potential applications in inflammation, angiogenesis, wound healing, regenerative medicine and infectious diseases. IntelliHep is exploiting novel technologies and intellectual property to deliver new heparin-based glycans as novel drug leads for specific diseases including Alzheimer’s disease and cancer. This is being achieved through in-house R&D and the development of strategic collaborative alliances with external partners.
IntelliHep has developed from work initiated by the Founders at the Universities of Birmingham and Liverpool, and is currently based in the MerseyBio incubator at Liverpool University.
Technology: Regenerative Medicine
Industry: Regenerative Medicine
Headquarters: Liverpool, Liverpool, United Kingdom
Founded Date: Undisclosed
Employees Number: Undisclosed
Funding Status: N/A
Investors Number: 1
Last Funding Type: Non-equity Assistance

Visit Website
Register and Claim Ownership